权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

King's College London Industrial Impact Fellowship in Drug Discovery

伦敦国王学院药物发现工业影响奖学金

基本信息

批准号：
BB/H004483/1
负责人：
Mark Ian Christie
金额：
$ 39.51万
依托单位：
King's College London
依托单位国家：
英国
项目类别：
Fellowship
财政年份：
2010
资助国家：
英国
起止时间：
2010 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=BB%2FH004483%2F1
关键词：
King College London Industrial Impact

项目摘要

Biomedical research in Pharmacology requires an understanding of how drugs exert their effects in complex mammalian systems in vivo, a drug discovery discipline essential to the successful translation of new medicines from basic research into the clinic. Surveys published by the pharmaceutical and biotechnology industries in the UK and the British Pharmacological Society have identified a critical lack of pre-clinical in vivo skills in the UK workforce and a decline in the quantity and quality of graduates in the core disciplines of in vivo science, drug metabolism, pharmacokinetic modelling and translational medicine. Research councils including the BBSRC are now investing in this area in an attempt to reverse this decline and build Integrative Mammalian Biology Centres across the UK, including King's College London (KCL). The Centre for Integrative Biomedicine (CIB) was established at KCL in 2007 and is joint funded by a BBSRC-led Capacity Building Award in Integrative Mammalian Biology. The research & training focus of the CIB is the study of whole animal function in normal and pathophysiological situations, and how fundamental processes in physiology and pharmacology maintain health at all stages of life. The in vivo capabilities of the CIB offer significant value to industrial drug discovery programmes, and with its virtual structure the CIB benefits from a range of specific discipline-focussed expertise located throughout KCL. The CIB is working with KCL to exploit experimental design to refine, reduce and replace animal experiments where possible and is fully committed to exploiting opportunities in the biophysical and pharmaceutical sciences areas of the School of Biomedical Sciences as they emerge. The Industrial Impact Fellowship will fund an experienced industry leader who will bring their in depth understanding of the research and skills requirements of the industry together with a knowledge of the drug discovery process from both a Pharma and Biotech perspective. The Fellow will be embedded within the CIB, co-located with the Head of the Centre, Prof. Susan Brain (to whom he will report), Prof Phil Moore and the Pharmaceutical Sciences Division. The Fellow will work on a part-time basis to deliver a coherent strategy to maximise the economic impact of the group and will be linked directly with KCL Business, in order to enhance the success of collaborative opportunities and extend opportunities in the CIB to the School of Biomedical Sciences. The work of the Fellow will focus on the two key priorities of partnership and education, expanding the Centre's contacts with Small to Medium Enterprises (SME's) and Biotech companies in UK & Europe. Key objectives for the work of the Fellow will be: 1) In depth analysis of the industry and a summary of the training & partnership opportunities for the CIB, 2) A review of the CIB's capabilities with an emphasis on its potential economic impact, 3) The generation of a range of marketing literature and workshops/marketing events 4) A regular dialogue with external and internal and external partners, leading to a sustainable network of new and existing collaborations with Pharma, SME and Biotech business 5) An increase in revenue from directly funded activity from industry or partnered funding applications in collaboration with the CIB's academics, together with an increase in the number and quality of industrial placement studentships 6) Regular review of how the activity of the CIB reflects the future research & training requirements of the industry sector The Fellow will work closely with internal partners, specifically the Principle Investigators at the CIB, researchers across the School of Biomedical & Health Sciences whose expertise may be applied to drug discovery, and King's Business. The Fellowship will start at the end of 2009 and be funded for 4 years, with continued support depending on the success of the initial post.

药理学中的生物医学研究需要了解药物如何在体内复杂的哺乳动物系统中发挥作用，这是一门药物发现学科，对于将新药从基础研究成功转化为临床至关重要。英国制药和生物技术行业以及英国药理学学会发布的调查发现，英国劳动力严重缺乏临床前体内技能，体内科学，药物代谢，药代动力学建模和转化医学等核心学科的毕业生数量和质量下降。包括BBSRC在内的研究委员会现在正在投资这一领域，试图扭转这种下降趋势，并在英国各地建立综合哺乳动物生物学中心，包括伦敦国王学院（KCL）。综合生物医学中心（CIB）于2007年在KCL成立，由BBSRC领导的综合哺乳动物生物学能力建设奖共同资助。CIB的研究和培训重点是研究正常和病理生理情况下的整体动物功能，以及生理学和药理学的基本过程如何在生命的各个阶段保持健康。CIB的体内功能为工业药物发现计划提供了重要价值，并且CIB的虚拟结构使其受益于KCL的一系列特定学科专业知识。CIB正在与KCL合作，利用实验设计来完善，减少和取代动物实验，并完全致力于利用生物医学科学学院生物物理和制药科学领域的机会。工业影响力奖学金将资助一位经验丰富的行业领导者，他们将深入了解行业的研究和技能要求，并从制药和生物技术的角度了解药物发现过程。该研究员将被嵌入CIB，与中心负责人Susan Brain教授（他将向其报告），Phil摩尔教授和药物科学部共同工作。该研究员将兼职工作，提供一个连贯的战略，以最大限度地提高集团的经济影响，并将直接与KCL业务，以提高合作机会的成功，并在CIB的机会扩展到生物医学科学学院。研究员的工作将侧重于伙伴关系和教育这两个关键优先事项，扩大中心与英国和欧洲中小企业和生物技术公司的联系。研究员工作的主要目标是：1）深入分析行业，总结CIB的培训和合作机会，2）审查CIB的能力，重点是其潜在的经济影响，3）生成一系列营销文献和研讨会/营销活动4）与外部和内部和外部合作伙伴定期对话，导致与制药，中小企业和生物技术业务的新的和现有的合作的可持续网络5）来自行业直接资助的活动或与CIB的学者合作的合作资助申请的收入增加，6）定期审查CIB的活动如何反映未来的研究和该研究员将与内部合作伙伴密切合作，特别是CIB的主要研究人员，生物医学与健康科学学院的研究人员，他们的专业知识可能适用于药物发现，以及King's Business。该研究金将于2009年底开始，供资期限为4年，并将根据最初职位的成功情况继续提供支助。